Kymera Therapeutics (KYMR) · KT-579
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: second half of 2026
data expected to be reported in the second half of 2026
EX-99.1 · filed · SEC filing
After
Stated timing: fourth quarter of 2026
Phase 1 clinical trial in healthy volunteers , with data expected in the fourth quarter of 2026
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/KYMR-kt-579-2026-08-05, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/KYMR-kt-579-2026-08-05
Kymera Therapeutics (KYMR) pipeline and stated timing · Calendar · Companies A–Z